Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults

• Published in: Clinical pharmacology in drug development Vol. 13; no. 5; pp. 534 - 548
• Main Authors: Lee, Caroline A., Schreiber, Stefan, Bressler, Brian, Adams, John W., Oh, Dooman Alexander, Tang, Yong Q., Zhang, Jinkun, Komori, Heather Kiyomi, Grundy, John S.
• Format: Journal Article
• Language: English
• Published: United States 01.05.2024
• Subjects: etrasimod; inflammatory disease; lymphocyte; pharmacokinetics; sphingosine 1‐phosphate receptor; inflammatory disease; pharmacokinetics; sphingosine 1-phosphate receptor; etrasimod; lymphocyte
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.1379

Etrasimod is an investigational, once‐daily, oral, selective sphingosine 1‐phosphate receptor 1,4,5 modulator in development for immune‐mediated inflammatory diseases (IMIDs). Here, we report the human safety, pharmacokinetics, and pharmacodynamics of etrasimod obtained from both a single ascending dose (SAD; 0.1‐5 mg) study and a multiple ascending dose (MAD; 0.35‐3 mg once daily) study. Overall, 99 healthy volunteers (SAD n = 40, MAD n = 59) completed the 2 studies. Evaluated single and multiple doses were well tolerated up to 3 mg without severe adverse events (AEs). Gastrointestinal disorders were the most common etrasimod‐related AEs. Over the evaluated single‐ and multiple‐dose ranges, dose‐proportional and marginally greater‐than‐dose‐proportional etrasimod plasma exposure were observed, respectively. At steady state, etrasimod oral clearance and half‐life mean values ranged from 1.0 to 1.2 L/h and 29.7 to 36.4 hours, respectively. Dose‐dependent total peripheral lymphocyte reductions occurred following etrasimod single and multiple dosing. Etrasimod multiple dosing resulted in reductions from baseline in total lymphocyte counts ranging from 41.1% to 68.8% after 21 days. Lymphocyte counts returned to normal range within 7 days following treatment discontinuation. Heart rate lowering from pretreatment baseline on etrasimod dosing was typically mild, with mean reductions seen after the first dose of up to 19.5 bpm (5 mg dose). The favorable safety, pharmacokinetic, and pharmacodynamic properties of etrasimod in humans supported its further development and warranted its investigation for treatment of IMIDs.